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INTRODUCTION
Renal cell carcinoma (RCC) is a well-known malignant 
disease of the urinary tract. Among various pathological 
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types, chromophobe renal cell carcinoma (chRCC) is the third 
most frequent subtype and accounts for 4%–6% of RCC cases 
[1]. Prognosis in chRCC is better than in other types of RCC, 
and chRCC is known to have originated from intercalated 
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cells of the collecting duct system [2]. Renal oncocytoma, a 
type of benign tumor that accounts for 3%–7% of all renal 
tumors [3], also originates from the collecting duct; therefore, 
chRCC and renal oncocytoma have overlapping morphologic, 
histochemical, immunohistochemical, and ultrastructural 
features [4]. As a result, it is sometimes difficult to distin-
guish the two tumor types in preoperative imaging studies. 
However, these tumors should be discriminated in order 
to make the decision to excise or observe because, unlike 
oncocytoma, chRCC can result in distant metastasis and 
even death due to disease progression [5].
A central stellate scar on enhanced computed tomo-
graphy (CT) and spoke-wheel-like appearance on angio-
graphy have been conventionally recognized as the features 
that distinguish oncocytoma from other renal tumors [6,7]. 
However, these features are observed in only one-third of 
oncocytomas, and RCC can often show these characteristics. 
Therefore, differentiating an oncocytoma from a chRCC 
preoperatively has been an issue. In this regard, several 
studies recently demonstrated that segmental enhancement 
inversion could be a distinct feature of oncocytoma [8,9]. 
The most widely used method to evaluate a renal mass 
before deciding whether to excise or not is the interpretation 
of CT characteristics. Numerous studies have investigated 
the discrimination and description of  renal tumors. In a 
review article, Dyer et al. [10] categorized renal masses into 
the ball and bean types, and concluded that their ball-versus-
bean strategy is a practical framework for identifying the 
imaging characteristics of renal tumors. Other investigations 
have demonstrated that the complexity of  the renal 
mass predicts its malignancy [11,12]. Even the multiphasic 
enhancement patterns of the renal mass and the presence 
of an angular interface with the renal parenchyma could be 
used as prognosticators [13,14]. We therefore conducted the 
current study to determine whether these various methods 
are helpful in distinguishing chRCC from renal oncocytoma 
in preoperative CT, and to integrate them in order to 
establish a simple diagnostic approach. 
MATERIALS AND METHODS
The protocol for this retrospective study was approved 
by Institutional Review Board of Severance Hospital. This 
study was performed in accordance with tenets of  the 
Declaration of  Helsinki. We retrospectively reviewed all 
pathological reports that had been submitted with sufficient 
amounts of tumor tissue after partial nephrectomy or radical 
nephrectomy in Severance Hospital between November 
2005 and June 2015. Operations had been performed by 
open, laparoscopic, video-assisted mini-incision, and robotic 
methods. Pathological reports originating from fine needle 
biopsies were excluded in this study. Two hundred forty 
nine patients who had been diagnosed with chRCC or 
renal oncocytoma were identified. Among them, 39 subjects 
without preoperative CT images, who had undergone 
only single or two-phase contrast-enhanced study, or with 
insufficient image quality performed in another hospital, 
were excluded. Finally, 210 patients who had undergone 
preoperative 3-phase (noncontrast, corticomedullary, and 
nephrogenic) or 4-phase (noncontrast, corticomedullary, 
nephrogenic, and excretory) CT, performed at least 3 months 
before surgery, were included in this analysis.
Two observers, who were urologists and blinded to the 
pathological results, reviewed the preoperative CT images. 
The laterality (left or right), size, and heterogeneity of the 
renal masses were observed. Size was determined as the 
maximal diameter in the axial plane. Each renal mass was 
categorized into either the ball pattern or bean pattern [10]. 
Briefly, a ball-type mass was defined as an exophytic mass 
that created a contour deformity in the renal margin with 
a pseudo-capsule. Bean-type mass was defined as a mass 
that retained the renal shape and infiltrated into the renal 
parenchyma as scaffolding. In addition, the existence of a 
central stellate scar and segmental inversion enhancement 
were examined. Segmental inversion enhancement was 
determined as previously described [8]; the tumor shows 
components of  relatively greater enhancement in the 
corticomedullary phase and lesser enhancement in the 
nephrogenic phase. Furthermore, we categorized renal 
masses into three groups according to their interface 
with the renal parenchyma: round (absence of an angular 
interface), equivocal (intermediate interface type), and 
angular (definite angular interface) [14]. Furthermore 
mass-enhancing patterns were described as early washout, 
gradual enhancement, and prolonged. Furthermore, tumor 
complexity was scored using the RENAL nephrometry score 
in accordance with the standard for each item [15]: radius (R), 
exophytic/endophytic (E), nearness to the collecting system 
(N), anterior/posterior (A), and location relative to the 
polar lines (L). To calculate the probability of malignancy 
using the RENAL nephrometry score, we figured out the 
probability using the RENAL nephrometry nomogram [11].
In this study, a total of  4 phases were used in the 
analysis. The corticomedullary, nephrogenic and excretory 
phases were acquired at 25–30 seconds, 100–120 seconds, 
and 5 minutes, respectively, after the start of  contrast 
injection. To analyze the mass-enhancing pattern of renal 
mass more accurately, we measured the Hounsfield units 
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(HUs) in each phase. We measured the mean, maximum, 
and minimum HUs in the axial image, which showed the 
maximal diameter of the mass. We excluded the calcification 
of the mass in measuring HU. To evaluate intratumoral 
heterogeneity, we also measured the standard deviation 
of  HU. We used the GE Centricity picture archiving 
and communication system (Centricity, GE Healthcare, 
Milwaukee, WI, USA) during the measurement procedure.
Data are presented as the median and interquartile 
range, unless otherwise indicated. For continuous variables, 
Mann-Whitney U test was used. For categorical variables, 
the chi-square test was used. The area under the curve 
(AUC) was used to determine the discrimination abilities of 
the RENAL nephrometry score nomogram. All statistical 
analyses were performed using IBM SPSS Statistics ver. 20.0 
(IBM Co., Armonk, NY, USA). Differences were considered 
statistically significant at p<0.05.
RESULTS
Table 1 lists pertinent study cohort data. There were 
51 renal oncocytomas and 120 chRCCs in the study cohort. 
There were no differences in gender, patient age, and 
operation methods between the two groups (p=0.575, p=0.321, 
Table 1. Clinical and demographic characteristics of study subjects
Characteristic Oncocytoma (n=51) Chromophobe RCC (n=120) p-value
Male sex 21 (41.2) 55 (45.8) 0.575
Age (y) 58 (46–64) 54 (46.3–61) 0.321
Body mass index (kg/m2) 23.1 (21.4–24.8) 23.8 (21.1–26.5) 0.190
Laterality 22 (43.1) 67 (55.8) 0.128
Operation method 0.890
   Open 15 (29.4) 39 (32.5)
   Video-assisted mini-incision 17 (33.3) 33 (27.5)
   Laparoscopy 9 (17.6) 24 (20)
   Robot 10 (19.6) 24 (20)
Radical nephrectomy 22 (43.1) 54 (45.0) 0.823
Tumor size (cm) 3.3 (2.3–6.7) 4 (2.2–6.7) 0.490
RENAL nephrometry score 7 (6–9) 8 (7–10) 0.095
Values are presented as number (%) or median (interquartile range).
RCC, renal cell carcinoma.
Table 2. Comparison of computed tomography findings between renal oncocytoma and chromophobe RCC
Characteristic Oncocytoma (n=51) Chromophobe RCC (n=120) p-value
Ball- or bean-type 0.084
   Ball-type 48 (94.1) 100 (83.3)
   Bean-type 3 (5.9) 20 (16.7)
Central stellate scar <0.001
   Absent 31 (60.8) 108 (90)
   Present 20 (39.2) 12 (10)
Angular interface 0.193
   Round 37 (72.5) 70 (58.3)
   Intermediate 3 (5.9) 14 (11.7)
   Angular 11 (21.6) 36 (30)
Segmental inversion enhancement 0.002
   Absent 28 (54.9) 94 (78.3)
   Present 23 (45.1) 26 (21.7)
Enhancement pattern 0.180
   Early washout 26 (51) 49 (40.8)
   Gradual enhancement 21 (41.2) 49 (40.8)
   Prolonged 4 (7.8) 22 (18.3)
Values are presented as number (%).
RCC, renal cell carcinoma.
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and p=0.890, respectively). Radical nephrectomy was 
performed in 43.1% and 45% of the patients in each group, 
respectively (p=0.823). The median tumor size of chRCC was 
a little bit larger than that of renal oncocytoma (4 cm vs. 
3.3 cm), but the difference was not statistically significant 
(p=0.490). Renal nephrometry score was also higher in 
the chRCC group (8 vs. 7) without statistical significance 
(p=0.095).
Table 2 shows the association of  CT findings with 
histological diagnoses of  renal masses. There were no 
differences in ball-/bean-type categorization and the shape of 
interface between groups (p=0.084 and p=0.193, respectively). 
Masses with a central stellate scar were more likely to be 
diagnosed as oncocytomas (p<0.001), as were renal tumors 
with segmental inversion enhancement (p=0.002). However, 
central stellate scar and segmental inversion enhancement 
were observed in only 39.2% and 45.1% of renal oncocytomas, 
respectively. There was no difference in the enhancement 
pattern of the masses between the two groups. The RENAL 
nephrometry score nomogram for discriminating malignancy 
between oncocytoma and chRCC revealed an AUC value of 
0.53 (95% confidence interval [CI], 0.43–0.62).
There was no difference in the mean HU value between 
oncocytoma and chRCC before enhancement; however, 
corticomedullary and nephrogenic phase attenuations were 
higher in oncocytoma than in chRCC (Fig. 1A). A similar 
relationship was seen with respect to maximal HU value 
in the tumor; however, there was no difference between 
the two groups with respect to the minimal HU value in 
tumor (Fig. 1B, C). The standard deviation of HU values 
in the tumor was higher in the corticomedullary phase in 
oncocytoma, whereas that of chRCC showed little change 
through the three phases. 
To observe changes in the excretory phase, we addi-
tionally analyzed 84 renal masses (28 oncocytomas 
and 56 chRCCs) that had all four phase images. The 
differences between the two groups were less than in the 
corticomedullary or nephrogenic phases; however, the 
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overall pattern was similar in the excretory phase (Fig. 2). 
In the excretory phase, the mean HU value was higher in 
oncocytoma than in chRCC (Fig. 2A). In addition, there were 
no differences in minimal HU values throughout the phases 
(Fig. 2C). 
Multivariate logistic regression analysis revealed an 
association between the presence of  central stellate scar 
(odds ratio [OR], 5.164; 95% CI, 2.051–13.004; p<0.001) and 
higher mean HU in nephrogenic phase (OR, 1.043 for each 
1 HU increase; 95% CI, 1.026–1.06; p<0.001) and oncocytoma. 
Receiver-operating characteristic curve analysis showed that 
the presence of a central stellate scar and a higher mean 
HU value in the nephrogenic phase were highly predictive 
of  renal oncocytoma (AUC=0.817, p<0.001), which was 
more predictive than the prediction model made with the 
presence of a central stellate scar and segmental inversion 
enhancement (AUC=0.723).
DISCUSSION
There are many ways to describe and evaluate renal 
mass, and efforts are constantly being undertaken to 
distinguish whether a tumor is benign or malignant. Dyer 
et al. [10] classified renal masses into the bean- and ball-
types according to radiological findings and compared this 
classification with the pathological results. The authors 
then attempted to classify each renal mass as either benign 
or malignant. Verma et al. [14] focused on the angular 
interface as a standard of judgment for determining benign 
and malignant. They used magnetic resonance images in 
their study instead of CT, and verified that the existence 
of angular interface reveals the benignity of the mass in 
>2-cm exophytic renal tumors. Multiphasic enhancement 
patterns of CT images have also been evaluated. Pierorazio 
et al. [13] interpreted multiphasic enhancement patterns of 
renal masses less than 4 cm in diameter using four-phase 
CT, and compared them with pathological results. Mullins 
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et al. [12] insisted that tumor complexity was related to 
the malignancy of the renal mass, and demonstrated that 
a high RENAL nephrometry score and male gender are 
associated with increased risk of malignancy and high-grade 
malignancy.
Regarding the distinction between benign and malig-
nant renal masses, distinguishing oncocytoma and chRCC is 
the one of the most challenging issues [4]. These two renal 
tumors are both known to originate from the intercalated 
cells of  the collecting duct [16]. Therefore, these tumors 
have common characteristics in morphologic, histochemical, 
immunohistochemical, and ultrastructural aspects [4]. In 
pathology, these two tumor types are usually distinguished 
based on the presence of  eosinophilic variants; however, 
research into this aspect is ongoing in the field of radiology 
[16]. In recent studies, the presence of  a central stellate 
scar and segmental enhancement inversion have attracted 
attention as radiological features of  renal oncocytoma 
[8,17]. The central stellate scar is a radiological as well 
as pathological f inding, and 25%–33% of  large renal 
oncocytomas show a central stellate scar in CT [17]. In the 
present study, 39.2% (20 of 51) of oncocytoma and 10% (12 
of 120) of  chRCC patients showed a central stellate scar. 
The difference was statistically significant (p<0.001), but 
this finding is not sufficient to distinguish oncocytoma 
from chRCC because only one-third of renal oncocytomas 
presented this feature.
Segmental enhancement inversion is another discrimi-
native finding of renal oncocytoma. In a meta-analysis to 
evaluate the diagnostic accuracy of segmental enhancement 
inversion from 4 studies of  307 patients, Schieda et al. 
[18] concluded that segmental enhancement inversion in 
contrast-enhanced biphasic multidetector CT is a specific 
feature of renal oncocytoma. However, the sensitivity of the 
studies varied (0%–6% to 59%–80%); this was considered 
a limitation. The sensitivity of  segmental enhancement 
inversion based on our results was 45%, which is not high 
enough. Nonetheless, only 22% of chRCC showed segmental 
inversion, and it was significantly lower than oncocytoma 
(p=0.002). These results indicate that segmental enhancement 
inversion might help distinguish these tumors to some 
degree. 
Pierorazio et al. [13] tried to analyze multiphasic en-
hancement patterns of  renal masses according to the 
f inal pathological results. In this report, the authors 
verified that significant differences were observed in 
peak enhancement and phase-specific enhancement by 
histology. They also demonstrated that oncocytoma showed 
patterns of peak enhancement in the nephrogenic phase 
and washout in delayed phase, while chRCC showed an 
intermediate enhancement pattern. However, these results 
are not powerful because of  the insufficient number of 
subjects in this study (13 oncocytomas and 10 chRCCs). 
In their comparative study of  CT appearance in renal 
oncocytoma and chRCC, Wu et al. [17] demonstrated that 
oncocytoma presents as a heterogeneous and hyperdense 
solid tumor, whereas chRCC presents as an isodense or 
mild hyperdense mass. In the present study, we measured 
the maximal, minimal, and mean HU values of  the pre-
enhancement, corticomedullary, and nephrogenic phases 
in order to evaluate the enhancement pattern on each 
phase, and furthermore measured the standard deviation 
of HU to estimate intratumoral heterogeneity. The mean 
and maximal HU values of oncocytoma were greater than 
chRCC in the corticomedullary and nephrogenic phases, 
which reveals that oncocytoma is more enhanced after dye 
injection than chRCC. The standard deviation of HU values 
was greater in oncocytoma than in chRCC, indicating that 
oncocytoma has more intratumoral heterogeneity than 
does chRCC. These features would be clinically useful to 
distinguish oncocytoma from chRCC. 
Beyond a qualitative description of the renal mass as 
heterogeneous or homogeneous, no quantitative method 
has yet been developed to measure the heterogeneity. 
Taura et al. [19] attempted a quantitative analysis of the 
heterogeneity of hepatic parenchymal enhancement using 
CT during arterial portography, and demonstrated that 
the higher fibrosis group exhibited significantly greater 
standard deviation values than did the lower fibrosis group. 
In addition, Kojima et al. [20] measured standard deviation 
as an index of the heterogeneity of renal cortical circulation, 
and verified that heterogeneity of renal cortical circulation 
is increased in hypertension and is associated with aging. 
To our knowledge, no study has estimated intratumoral 
heterogeneity by measuring the standard deviation of HU 
values.
Limitations of the present study include its retrospective 
nature and relatively small subject number. Because 
we included only pathologically conf irmed patients, 
radiologically conf irmed oncocytomas that were not 
surgically excised and renal tumors treated by nonsurgical 
methods such as cryotherapy were excluded, which could be 
a selection bias. In addition, we compared only oncocytoma 
and chRCC; evaluations of  other renal masses were not 
conducted. However, chRCC is the renal mass type that is 
most commonly misdiagnosed as renal oncocytoma is chRCC, 
and we therefore tried to identify a method to distinguish 
the two tumors preoperatively. Furthermore we could not 
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measure HU values and standard deviations in the whole 
renal tumor, because of the marginal irregularity of the 
masses.
CONCLUSIONS
Oncocytoma is more likely to show segmental 
enhancement inversion and a central stellate scar. However, 
these features were not common even in oncocytomas and 
are insufficient for preoperative clinical distinction of these 
two types of renal masses. Oncocytoma presented higher 
HU values in the corticomedullary and nephrogenic. In 
addition, oncocytoma showed greater standard deviation 
of HU values than did chRCC. Collectively, these results 
indicate that the central stellate scar and higher mean HU 
values in the nephrogenic phase are highly predictive of 
renal oncocytoma. These results could be clinically useful 
in differentiating renal oncocytoma from chRCC before 
surgical treatment.
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